Journal article
Abciximab in Acute Ischemic Stroke
Abstract
BACKGROUND AND PURPOSE: Abciximab is a potent parenterally administered platelet glycoprotein IIb/IIIa antagonist. Because this agent has been shown to improve outcomes in coronary artery disease, there is interest to evaluate whether it could improve cerebral perfusion and outcomes after ischemic stroke. This study was designed to evaluate the safety of abciximab in acute ischemic stroke and to obtain pilot efficacy data.
METHODS: We conducted …
Authors
Investigators TAIIS
Journal
Stroke, Vol. 31, No. 3, pp. 601–609
Publisher
Wolters Kluwer
Publication Date
3 2000
DOI
10.1161/01.str.31.3.601
ISSN
0039-2499